TRIB TRINITY BIOTECH PLC

Nasdaq trinitybiotech.com


$ 0.97 $ -0.01 (-0.8 %)    

Wednesday, 05-Nov-2025 15:59:19 EST
QQQ $ 622.38 $ 4.94 (0.8 %)
DIA $ 473.04 $ 2.23 (0.47 %)
SPY $ 677.28 $ 2.47 (0.37 %)
TLT $ 89.01 $ -0.57 (-0.64 %)
GLD $ 365.20 $ 0.10 (0.03 %)
$ 0.992
$ 1.01
$ 0.90 x 750
$ 1.07 x 50
$ 0.97 - $ 1.04
$ 0.88 - $ 17.20
155,016
na
17.82M
$ 1.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 trinity-biotech-regains-nasdaq-compliance

Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and dia...

 trinity-biotech-announces-clinical-trial-results-demonstrating-technical-breakthrough-and-de-risking-commercial-pathway-for-its-next-gen-continuous-glucose-monitoring-technology-called-cgm

Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes managemen...

 mhra-says-received-reports-describing-positive-bias-in-hba1c-results-delivered-by-trinity-biotech-premier-hb9210-hba1c-analyser-says-positive-bias-in-hba1c-results-resulted-in-patients-being-incorrectly-diagnosed-as-pre-diabetic-or-diabetic-trinity-biotech-committed-to-updating-intended-use-statement-in-the-instructions-for-use

https://www.gov.uk/drug-device-alerts/trinity-biotech-premier-hb9210-hba1c-analyser-risk-of-positive-bias-and-updates-to-instru...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION